A. Rodrigues

2 papers in the library · publishing 2020-2021

Papers

The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway.

Journal of Psychiatric Research September 30, 2021 A. Camargo, A. P. Dalmagro, I. A. Wolin et al.

A single injection of ketamine (5 mg/kg) given to mice one week before exposure to the inflammatory stressors lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-α) prevented depressive-like behaviors measured in the tail suspension test and splash test. A lower dose (1 mg/kg) did not have this effect. LPS increased markers of microglial activation and components of the NLRP3 inflammasome signaling pathway in the ventral hippocampus, while TNF-α only increased two of those components. Ketamine at 5 mg/kg, but not 1 mg/kg, blocked these increases. The findings suggest ketamine can promote resilience against inflammation-induced depressive-like behavior by suppressing NLRP3 inflammasome signaling.

DOI: 10.1016/j.jpsychires.2021.09.057 Medicine Biology

Guanosine potentiates the antidepressant-like effect of subthreshold doses of ketamine: Possible role of pro-synaptogenic signaling pathway.

Journal of Affective Disorders June 1, 2020 A. Camargo, A. P. Dalmagro, A. Zeni et al.

Combining low doses of ketamine and guanosine produces an antidepressant-like effect in mice, likely by activating synaptogenic signaling pathways in the hippocampus and prefrontal cortex. The treatment increased phosphorylation of mTOR and p70S6K in the hippocampus and raised levels of synaptic proteins PSD-95 and GluA1 in the prefrontal cortex. A single co-administration also reversed depressive-like behavior induced by chronic corticosterone exposure. The authors suggest that guanosine could augment ketamine's effects, potentially offering a therapeutic strategy for treatment-resistant depression.

DOI: 10.1016/j.jad.2020.03.186 Medicine